Literature DB >> 35139906

Correction to: Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.

Francisco Mera-Cordero1,2, Sara Bonet-Monne3,4, Jesús Almeda-Ortega3,5, Ana García-Sangenís3,6, Oriol Cunillera-Puèrtolas7, Sara Contreras-Martos3,5, Gemma Alvarez-Muñoz3,8, Ramon Monfà3,6, Marina Balanzó-Joué3,4, Rosa Morros3,6,9, Betlem Salvador-Gonzalez3.   

Abstract

Entities:  

Year:  2022        PMID: 35139906      PMCID: PMC8827194          DOI: 10.1186/s13063-022-06073-7

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


× No keyword cloud information.
Correction to: Trials 23, 19 (2022) https://doi.org/10.1186/s13063-021-05951-w Following the publication of the original article [1], we were notified that the author names have been incorrectly tagged (part of the last names had originally been tagged as first name). Originally published author names: Francisco Mera Cordero, Sara Bonet Monne, Jesús Almeda Ortega, Ana García-Sangenís, Oriol Cunillera Puèrtolas, Sara Contreras-Martos, Gemma Alvarez Muñoz, Ramon Monfà Escolà, Marina Balanzó Joué, Rosa Morros Pedrós and Betlem Salvador-Gonzalez Corrected author names: Francisco Mera-Cordero, Sara Bonet-Monne, Jesús Almeda-Ortega, Ana García-Sangenís, Oriol Cunillera-Puèrtolas, Sara Contreras-Martos, Gemma Alvarez-Muñoz, Ramon Monfa, Marina Balanzo-Joué, Rosa Morros, Betlem Salvador-Gonzalez The original article has been corrected.
  1 in total

1.  Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.

Authors:  Francisco Mera-Cordero; Sara Bonet-Monne; Jesús Almeda-Ortega; Ana García-Sangenís; Oriol Cunillera-Puèrtolas; Sara Contreras-Martos; Gemma Alvarez-Muñoz; Ramon Monfà; Marina Balanzo-Joué; Rosa Morros; Betlem Salvador-Gonzalez
Journal:  Trials       Date:  2022-01-06       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.